Table 1.

Demographic and clinical variables of the study sample by CRP category.

		CRP ≤ 2 mg/L (N = 21)	CRP > 2 mg/L (N = 19)	p value
Age	Mean (SD)	34.0 (10.6)	38.5 (11.4)	0.206a
Sex	Male, N (%)	9 (42.9)	3 (15.8)	0.089b
Race	White, N (%)	13 (61.9)	11 (57.9)	0.967c
	Black, N (%)	7 (33.3)	7 (36.8)
	Asian, N (%)	1 (4.8)	1 (5.3)
BMI	Mean (SD)	26.0 (4.3)	31.2 (5.9)	0.003a
CRP (mg/L)	Median (IQR)	1.0 (1.1)	3.63 (1.4)	<0.001d
Inflammatory Scoref	Mean (SD)	−1.2 (2.5)	1.2 (3.1)	0.011a
HAM-D	Mean (SD)	21.5 (3.2)	22.0 (3.9)	0.677a
IDS-SR	Mean (SD)	34.5 (9.4)	39.2 (5.7)	0.069a
EEfRT (proportion hard choices per % probability win)g
12%, Post-Placebo	Mean (SD)	0.14 (0.22)	0.08 (0.12)	0.309e
12%, Post-L-DOPA	Mean (SD)	0.14 (0.22)	0.09 (0.16)	0.487e
50%, Post-Placebo	Mean (SD)	0.33 (0.24)	0.23 (0.22)	0.202e
50%, Post-L-DOPA	Mean (SD)	0.34 (0.25)	0.23 (0.26)	0.218e
88%, Post-Placebo	Mean (SD)	0.58 (0.18)	0.51 (0.33)	0.428e
88%, Post-L-DOPA	Mean (SD)	0.52 (0.21)	0.53 (0.32)	0.845e
Anhedonia (momentary SHAPS score)
SHAPS Pre-Placebo	Mean (SD)	4.0 (3.5)	5.4 (4.3)	0.259e
SHAPS Post-Placebo	Mean (SD)	3.1 (3.3)	5.3 (4.4)	0.091e
SHAPS Pre-L-DOPA	Mean (SD)	4.1 (3.1)	4.9 (4.2)	0.466e
SHAPS Post-L-DOPA	Mean (SD)	3.6 (3.4)	3.9 (4.4)	0.762e
Plasma L-DOPA (nM)	Median (IQR)	5650 (6085)	7370 (6130)	0.215d
Plasma DA (nM)	Median (IQR)	9.72 (5.84)	9.08 (6.86)	0.893d

CRP C-reactive protein, BMI body mass index, DA dopamine, EEfRT Effort Expenditure for Rewards Task, HAM-D Hamilton Depression Rating Scale, L-DOPA levodopa, SHAPS Snaith-Hamilton Pleasure Scale, SD standard deviation, IQR interquartile range.

Bold text indicates p < 0.05.

^aT-test.

^bFisher’s exact test.

^cPearson’s Chi-squared test.

^dKruskal–Wallis rank sum test.

^eMultivariate linear ANOVA.

^fn = 20 for CRP ≤ 2 mg/L group.

^gn = 17 for CRP > 2 mg/L group.